In this video interview, Iddo Peleg, CEO and co-founder at Yonalink, highlights the need for a satellite model in bringing clinical trials to more rural locations.

Ron Lanton, Partner, Lanton Law, shares his insights on the legal and political consequences of the NIH funding freeze and potential options for continuing research.

Xolair (omalizumab) shows superior efficacy and safety compared to multi-allergen oral immunotherapy in treating food ...

Ron Lanton, Partner, Lanton Law, discusses how stakeholders must navigate funding future clinical research amid NIH budget cuts.

Phase III PRESTIGE-AF trial shows that direct oral anticoagulants significantly lower the risk of ischemic stroke in ...

Beyond direct costs, CROs incur significant expenses in the pre-award phase, creating strategic proposals to compete for trial contracts from sponsors. These activities, often unpaid, cost millions ...

In an interview with Applied Clinical Trials Associate Editor Don Tracy, Shakthi Kumar, chief strategy & business officer, ...

In this video interview, Vera Pomerantseva, director of product management, RBQM, eClinical Solutions, talks FDA’s latest ...

In this video interview, Pomerantseva, director of product management, RBQM, eClinical Solutions, discusses the new guidance ...

External control arms, as an integral part of clinical development, present many potential opportunities for sponsors and ...

A tool-based approach can significantly aid in the harmonization of regulatory requirements, mitigate inadvertent risks, and ...

Following initial positive results shared by Teva and Sanofi in December 2024, new data shows duvakitug (TEV’574/SAR447189) ...